glp-1 nad Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies GLP-1 and the kidney: from
Description
GLP-1RAs stimulate insulin secretion in a glucose-dependent manner, therefore, reduce the risk of hypoglycemia
This new twin therapy includes not only a GLP-1 Receptor Agonist, but also a Glucose-dependent insulinotropic polypeptide (GIP), which magnifies the therapeutic effectiveness
These findings demonstrate that hypoxia does not affect the basal GLP-1 secretion but decreases nutrient-stimulated GLP-1 secretion
Hartcoherentie is ook wetenschappelijk onderbouwd
Improvement of Glucose Tolerance by Food Factors Having Glucagon-Like Peptide-1 Releasing Activity
